Posts

KRAS mutations in Breast cancer may be treatable

For decades, mutations in #KRAS have been known to cause cancers in multiple organs and the gene KRAS itself was considered ‘undruggable’. Of the many mutations, KRAS-G12C is known to occur in nearly 13% of #NSCLC cases. There were no known treatments that can target KRAS-G12C mutation until recently. May 2021 heralded the #fdaapproval of Sotorasib, granted to #amgen, for treatment of #lungcancer with the G12C mutation in KRAS. Exciting results showed a reduction in tumour burden in more than 37% of the trial participants. This paves the way for testing the efficacy of the drug in multiple other cancers harbouring this driver mutation.
Our data identified nearly 7.8% of breast cancer #FFPE samples bearing the KRAS-G12C mutation, bringing hope of this #drug to people with #breastcancer.

Sapien’s samples and real world data enables validation of a new Indian breast cancer test with high concordance to OncotypeDx test

In 2014, Sapien partnered with Oncostem Diagnostics to provide our curated breast cancer FFPE blocks and RWE 5 years treatment and recurrence outcome data to enable the validation of a new test to accurately determine the risk of recurrence in early stage breast ca patients. A key goal of the test was to identify patients at low risk that could avoid chemotherapy and its side-effects, a major benefit to #cancerpatients (see Sapien referenced in this & previous papers).

https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.3495

It’s gratifying to see their first test, canAssist Breast for hormone positive breast cancer patients, perform equivalent to the gold standard Oncotype Dx test, a more expensive and higher TAT for Indian patients.

Our deep collection of matched FFPE blocks and longitudinal RWE data to enable precision medicine tests has continued to grow, both in breast cancer (>10,000 cases), and in #colorectalcancer, #lungcancer, #oralcancer, #kidneycancer, #ovariancancer #glioma #liver cancers. Contact us at  queries@sapienbio.com

Kidney cancer rarely affects children. The most common one is Wilms’ tumor, also called nephroblastoma, that accounts for up to 95% of childhood kidney cancers, with most children being below the age of 5 years. It is a fast growing tumor that can spread (metastasize). It is usually treated by surgery, followed by radiation and chemotherapy. Commonly used chemo drugs are doxorubicin, vincristine and actinomycin D. Overall survival rates tend to be high (>90%), with favourable histopathology diagnosis and timely treatment.

 

https://www.indiacancersurgerysite.com/wilms-tumor-treatment-india.html

September is Childhood Cancer Awareness Month. 30,000 children in India and 10 times that number worldwide develop cancer every year. There is a lack of awareness and timely diagnosis to treat them. Sapien will be sharing the Indian cancer data it has throughout September, starting with colorectal cancer.

Resources: https://www.worldchildcancer.org/, https://www.indiancancersociety.org/, https://www.childrenwithcancer.org.uk/, https://curechildhoodcancer.org/,

Rejig.HydStartups kick-off G.R.O.W

 

First of the Rejig.Hyderabad marathon sessions happened yesterday evening. A total of 13 companies, broadly in area of healthcare, were given 3 minutes each to pitch virtually in front of 4 mentors: @Ambuj Chaturvedi, @Vijay Bhaskar, @Neetika Maheshwari, @Vivek Bhargava, with @Paridhi Gupta and @Ramjee Pallela diligently keeping us all on time. It was heartening to get instant mentor feedback to our pitch for growth funds in that they all said Sapien had clearly proven traction and market validation for its services and products. They were keen to see our roadmap for scale-up, product and IP potential, and interested in seeing how the structured patient data we have built up carefully for breast, lung, renal, colorectal, gliomas etc. could be made available for research at universities to build data analytics & AI capabilities.  I look forward to the 1-on-1 mentoring sessions to help refine our pitch for success.

To contact us – please write to queries@sapienbio.com